ArticleAnnals of surgery1994
Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
Article in Annals of surgery, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.British journal of cancer · 2003Pooled it
- Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.Annals of surgery · 2001Trial
- Article
- Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.PloS one · 2015Article
- Precision medicine and personalized breast cancer: combination pertuzumab therapy.Pharmacogenomics and personalized medicine · 2014Review
- Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer.Journal of breast cancer · 2013Article
- Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.Medical oncology (Northwood, London, England) · 2012Article
- Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division.Acta naturae · 2011Article
- Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer.European radiology · 2010Article
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Experimental and molecular pathology · 2009Review
- Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study.Oncology reports · 2008Article
- Metaplastic mammary carcinoma with osteoclast-like giant cells: identical point mutation of p53 gene only identified in both the intraductal and sarcomatous components.Virchows Archiv : an international journal of pathology · 2004Article
- Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.Breast cancer research : BCR · 2004Article
- The likely transformation of papillary thyroid carcinoma into anaplastic carcinoma during postoperative radioactive iodine-131 therapy: report of a case.Surgery today · 2000Article
- Homogeneously staining regions in 223 breast carcinomas: cytogenetic and clinicopathological correlations.British journal of cancer · 1998Article
- Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up.British journal of cancer · 1998Article
- Biological indices in the assessment of breast cancer.Clinical molecular pathology · 1995Article
- The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.Annals of surgery · 1995Article
- Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.Annals of surgery · 1995Article
- Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.Annals of surgery · 1995Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveOverexpression of the p53 and HER-2/neu oncogenes are the two most common genetic abnormalities associated with breast cancer. Shorter survival time has been reported in patients with tumors with p53 or HER-2/neu. This report analyzes a retrospective cohort of early stage breast cancers for both oncogenes and relates overexpression to clinicopathologic parameters and survival.
methodsImmunostaining for p53 and HER-2/neu was performed on 230 paraffin-embedded specimens of stage I and II breast cancers diagnosed and treated at Duke University Medical Center between 1984 and 1987. Positive staining for both p53 and HER-2/neu in paraffin-embedded tissues indicates an underlying genetic abnormality: point mutations in the p53 gene and amplification of the HER-2/neu gene.
resultsIn this cohort of patients, 24% were positive for p53 and 17% for HER-2/neu. Four per cent were positive for both oncogenes. Significant correlations were found between p53 immunostaining and increasing tumor size, stage, and low estrogen and progesterone receptor contents. Univariate analysis showed that p53 and HER-2/neu were indicators of overall and failure-free survival. An additive effect on survival was observed in patients with both oncogene abnormalities. Nodal status, HER-2/neu, and p53 all attained independent prognostic value in a multivariate analysis.
conclusionsThe p53 and HER-2/neu oncogenes have proven but limited prognostic value. An approach that combines several molecular genetic markers with established pathologic criteria may help physicians to make more accurate predictions of prognosis in patients with early stage breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.